MARKET

BMY

BMY

Bristol-Myers
NYSE

Real-time Quotes | Nasdaq Last Sale

60.45
+0.02
+0.03%
After Hours: 60.54 +0.09 +0.15% 19:35 03/08 EST
OPEN
60.60
PREV CLOSE
60.43
HIGH
61.72
LOW
60.13
VOLUME
10.62M
TURNOVER
--
52 WEEK HIGH
67.16
52 WEEK LOW
45.76
MARKET CAP
135.44B
P/E (TTM)
-15.0530
1D
5D
1M
3M
1Y
5Y
Global Byler Disease Market Things to Focus on to Ensure Long-term Success | AstraZeneca PLC, Pfizer Inc, Bristol-Myers Squibb Company, Gilead Science Inc., Johnson & Johnson Private Limited.
Mar 08, 2021 (MARKITWIRED via COMTEX) -- VALLEY COTTAGE, N.Y. -Impact of COVID-19 on the Healthcare Industry The COVID-19 pandemic has causedsevere impacts...
Markitwired · 4h ago
Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq
Zacks.com · 5h ago
ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast – 2035
ABNewswire · 6h ago
Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL
Zacks.com · 6h ago
NIH starts trial enrollment for Bristol/Pfizer's Eliquis for blood clots in COVID patients
The National Institutes of Health (NIH) has begun enrollment in the third and final phase 3 trial evaluating the effectiveness of Bristol Myers Squibb (BMY) and Pfizer's (PFE) blood thinner
Seekingalpha · 7h ago
Atrial Fibrillation Surgery Devices Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030
Heraldkeepers · 9h ago
Autoimmune Diseases Treatment Market Research Report 2021 Elaborate Analysis With Growth Forecast To 2028
Heraldkeepers · 9h ago
Bile Duct Cancer Market Share, Size, Trends, Industry Analysis to 2027 by Disease Type; By Technology; By Specialty; By End-Use; By Regions
Mar 08, 2021 (Heraldkeepers) -- The Global Bile Duct Cancer Market share is segmented on the lines of its technology, treatment, application and regional....
Heraldkeepers · 9h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMY. Analyze the recent business situations of Bristol-Myers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMY stock price target is 75.53 with a high estimate of 86.00 and a low estimate of 66.00.
EPS
Institutional Holdings
Institutions: 2.98K
Institutional Holdings: 1.74B
% Owned: 77.45%
Shares Outstanding: 2.24B
TypeInstitutionsShares
Increased
922
75.49M
New
348
6.96M
Decreased
852
90.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Judge
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President/Director of Investor Relations
John Elicker
Executive Vice President
Nadim Ahmed
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Kathryn Metcalfe
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Senior Vice President/Chief Information Officer
Paul von Autenried
Senior Vice President/Chief Compliance Officer
Adam Dubow
Senior Vice President/Controller
Karen Santiago
Senior Vice President
Joseph Eid
Vice President/Director of Investor Relations/IR Contact Officer
Tim Power
Lead Director/Independent Director
Vicki Sato
Lead Director/Independent Director
vicki Sato
Independent Director
Peter Arduini
Independent Director
Robert Bertolini
Independent Director
Michael Bonney
Independent Director
Matthew Emmens
Independent Director
Julia Haller
Independent Director
Dinesh Paliwal
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Theodore Samuels
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
Declaration Date
Dividend Per Share
Ex-Div Date
03/01/2021
Dividend USD 0.49
03/31/2021
12/10/2020
Dividend USD 0.49
12/31/2020
09/10/2020
Dividend USD 0.45
10/01/2020
06/11/2020
Dividend USD 0.45
07/02/2020
03/02/2020
Dividend USD 0.45
04/02/2020
12/05/2019
Dividend USD 0.45
01/02/2020
09/11/2019
Dividend USD 0.41
10/03/2019
06/13/2019
Dividend USD 0.41
07/03/2019
03/07/2019
Dividend USD 0.41
04/04/2019
12/06/2018
Dividend USD 0.41
01/03/2019
09/12/2018
Dividend USD 0.4
10/04/2018
06/14/2018
Dividend USD 0.4
07/05/2018
03/01/2018
Dividend USD 0.4
04/05/2018
12/07/2017
Dividend USD 0.4
01/04/2018
09/13/2017
Dividend USD 0.39
10/05/2017
06/14/2017
Dividend USD 0.39
07/05/2017
03/03/2017
Dividend USD 0.39
04/05/2017
12/09/2016
Dividend USD 0.39
01/04/2017
08/04/2016
Dividend USD 0.38
10/05/2016
06/13/2016
Dividend USD 0.38
06/29/2016
03/04/2016
Dividend USD 0.38
03/30/2016
12/10/2015
Dividend USD 0.38
12/30/2015
09/18/2015
Dividend USD 0.37
09/30/2015
06/19/2015
Dividend USD 0.37
07/01/2015
03/05/2015
Dividend USD 0.37
04/01/2015
12/10/2014
Dividend USD 0.37
12/30/2014
09/17/2014
Dividend USD 0.36
10/01/2014
06/18/2014
Dividend USD 0.36
07/01/2014
03/04/2014
Dividend USD 0.36
04/02/2014
12/19/2013
Dividend USD 0.36
12/31/2013
09/18/2013
Dividend USD 0.35
10/02/2013
06/20/2013
Dividend USD 0.35
07/02/2013
About BMY
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.